Skip to main content

Table 3 OS analysis for all patients

From: The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer

Characteristics

 

RMSTb (95%CI)

HRc (95%CI)

P valuea

Interaction p

Non-chemotherapy

Chemotherapy

Total

–

53.7 (51.9–55.2)

56.2 (55.2–57.0)

0.580 (0.388–0.866)

0.007

–

Sex

Male

53.2 (50.7–55.1)

55.9 (54.4–57.0)

0.592 (0.360–0.971)

0.035

0.751

Female

54.5 (51.7–56.4)

56.8 (54.8–58.0)

0.560 (0.282–1.112)

0.093

 

Age (years)

≤55

54.3 (48.0–57.6)

56.3 (53.8–57.8)

0.620 (0.225–1.708)

0.350

0.844

56–60

55.4 (47.4–58.5)

56.8 (54.4–58.2)

0.725 (0.199–2.634)

0.623

 

61–65

53.3 (46.5–56.9)

55.7 (52.9–57.5)

0.636 (0.240–1.683)

0.357

 

66–70

53.2 (48.1–56.4)

57.3 (53.6–58.8)

0.355 (0.118–1.063)

0.053

 

> 70

53.6 (50.9–55.7)

54.6 (49.5–57.1)

0.834 (0.371–1.875)

0.660

 

Location

Rectum

52.2 (49.2–54.5)

55.6 (53.9–56.9)

0.539 (0.323–0.900)

0.016

0.479

Colon

55.2 (52.8–56.9)

56.9 (55.4–58.1)

0.612 (0.321–1.168)

0.132

 

Size (cm)

≤5.0

54.0 (51.2–55.8)

56.1 (54.5–57.2)

0.621 (0.361–1.067)

0.081

0.255

> 5.0

53.7 (50.5–55.8)

56.3 (54.5–57.5)

0.561 (0.306–1.028)

0.058

 

Differentiation

Well-moderate

53.9 (52.0–55.4)

56.3 (55.2–57.2)

0.569 (0.373–0.868)

0.008

0.396

Poor

52.0 (43.2–56.6)

54.7 (46.8–57.8)

0.662 (0.177–2.471)

0.534

 

T category

3

56.4 (53.7–58.0)

57.6 (55.5–58.6)

0.654 (0.277–1.543)

0.328

0.382

4

51.8 (49.2–54.0)

55.6 (54.2–56.8)

0.501 (0.318–0.791)

0.002

 

CEAd (ng/mL)

< 5

54.6 (51.9–56.4)

56.7 (55.3–57.8)

0.585 (0.323–1.060)

0.073

0.482

≥5

53.5 (50.1–55.7)

55.1 (52.8–56.8)

0.734 (0.384–1.404)

0.348

 

Examined lymph nodes

< 12

52.0 (47.5–54.9)

53.6 (50.2–55.6)

0.793 (0.414–1.520)

0.483

0.415

≥12

54.5 (52.3–56.0)

57.1 (55.9–57.9)

0.500 (0.300–0.835)

0.007

 

PLRe

≤130

56.0 (53.6–57.6)

56.0 (54.3–57.2)

0.983 (0.528–1.829)

0.956

0.027

> 130

51.3 (47.8–53.7)

56.5 (54.8–57.7)

0.371 (0.212–0.649)

< 0.001

 
  1. a P value of the log-rank test
  2. b RMST: the restricted mean survival time
  3. c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
  4. d CEA: carcinoembryonic antigen
  5. e PLR: platelet to lymphocyte ratio